Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Analysis of Investments

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities

Medtronic PLC, adjustment to net income attributable to Medtronic

US$ in millions

Microsoft Excel
12 months ended: Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Net income attributable to Medtronic (as reported)
Add: Unrealized gain (loss) on investment securities
Net income attributable to Medtronic (adjusted)

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).


The analysis of the reported and adjusted net income for the company over the six-year period reveals notable fluctuations and certain trends.

Reported Net Income Attributable to Medtronic
The reported net income shows variability with a peak in April 29, 2022, at $5,039 million, followed by a marked decline in the subsequent year to $3,758 million. There is a slight decrease in April 26, 2024, with $3,676 million, before the figure rises again to $4,662 million in April 25, 2025. The overall pattern indicates volatility without a clear long-term upward or downward trajectory.
Adjusted Net Income Attributable to Medtronic
The adjusted net income mirrors the fluctuations seen in the reported figures but tends to be slightly higher or lower at different points, reflecting the adjustments made. Adjusted net income peaks less sharply at $4,738 million in April 29, 2022, and declines to $3,709 million the following year. In April 26, 2024, it shows a marginal increase to $3,722 million, then rises significantly to $4,811 million by April 25, 2025. This adjusted measure also displays volatility but demonstrates a more moderate peak and trough pattern compared to the reported net income.

Overall, both reported and adjusted net incomes indicate periods of strong earnings interspersed with notable declines. The year ending April 29, 2022, represents a high point, followed by a decrease in income in subsequent years, before recovering towards the end of the period under review. The adjusted net income tends to smooth some of the more extreme variations seen in the reported net income, highlighting the impact of adjustments on the company's financial results.


Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)

Medtronic PLC, adjusted profitability ratios

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).


Net Profit Margin
The reported net profit margin exhibits a fluctuating pattern over the observed periods. Initially, it decreased from 16.56% in April 2020 to 11.97% in April 2021, before partially recovering to 15.9% in April 2022. Subsequently, it declined again to 11.36% by April 2024, followed by an increase to 13.9% in April 2025. The adjusted net profit margin follows a similar trend but shows slightly higher values at most points, reflecting adjustments that marginally improve the margin perspective. The overall volatility indicates cyclical challenges impacting profitability margins, with some recovery noted in the latest period.
Return on Equity (ROE)
Reported ROE demonstrates significant variability, starting at 9.44% in April 2020 and declining sharply to 7.01% in April 2021. It then rose to 9.59% in April 2022 before descending again close to 7.32% by April 2024. A notable improvement occurs in April 2025, with ROE rising to 9.71%. Adjusted ROE values mirror this pattern but generally show slightly higher figures, particularly in the final period where it reaches 10.02%, suggesting an enhanced return on shareholders' equity after adjustments. This pattern points to a performance fluctuating due to varying operational efficiency or capital structure impacts.
Return on Assets (ROA)
The reported ROA follows a similar fluctuation pattern as seen in net profit margin and ROE. From 5.28% in April 2020, it falls to a low of 3.87% in April 2021, rebounds to 5.54% in April 2022, then declines slightly to around 4.09% by April 2024. By April 2025, ROA improves again to 5.09%. Adjusted ROA values remain close to reported numbers, with marginal increases in later periods, peaking at 5.25% in April 2025. This trend indicates varying efficiency in asset utilization over time, with recent improvements suggesting better asset management or operational gains.

Medtronic PLC, Profitability Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic
Net sales
Profitability Ratio
Net profit margin1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Medtronic
Net sales
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

2025 Calculations

1 Net profit margin = 100 × Net income attributable to Medtronic ÷ Net sales
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income attributable to Medtronic ÷ Net sales
= 100 × ÷ =


Net Income Trends
The reported net income attributable to the company demonstrates a fluctuating pattern over the examined periods. It peaked initially in 2020 at 4,789 million US dollars, followed by a significant decline in 2021 to 3,606 million. This was succeeded by a recovery in 2022, reaching 5,039 million. Subsequent years show a decline again in 2023 and 2024, with values of 3,758 million and 3,676 million respectively, before increasing to 4,662 million in 2025.
Adjusted net income similarly exhibits variability but with relatively smoother transitions. Starting at 4,834 million in 2020, it decreases in 2021 to 3,698 million, then to 4,738 million in 2022. The following years maintain a similar trend as the reported figures, with a slight decrease in 2023 and 2024 (3,709 million and 3,722 million, respectively) and an increase to 4,811 million in 2025.
Net Profit Margin Trends
The reported net profit margin percentage follows a generally consistent pattern of volatility as observed in net income. The margin stood at 16.56% in 2020, then decreased to 11.97% in 2021. A rebound occurred in 2022 to 15.9%, followed by a decline in 2023 and 2024 to 12.03% and 11.36%, respectively, before a moderate recovery to 13.9% in 2025.
Adjusted net profit margin shows a similar trend but with marginally higher values in most years. It started at 16.72% in 2020, dipped to 12.28% in 2021, then rose to 14.95% in 2022. Subsequent declines in 2023 and 2024 are noted at 11.88% and 11.5%, followed by an increase to 14.35% in 2025.
Summary of Insights
Both reported and adjusted figures indicate cyclical fluctuations in profitability and net income over the six-year period. The company experiences notable declines in performance in 2021 and mid-period troughs again in 2023-2024. Recovery phases are evident in 2022 and in the latest year, 2025. Margins reflect a similar trajectory, albeit adjusted margins remain slightly more stable and consistently higher than reported margins.
The data suggests sensitivity to external or operational factors impacting earnings and profitability, with the adjusted measures providing a moderated view of underlying earnings power. The recent improvement in 2025 signals a possible return to stronger earnings and profitability levels.

Adjusted Return on Equity (ROE)

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic
Shareholders’ equity
Profitability Ratio
ROE1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Medtronic
Shareholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

2025 Calculations

1 ROE = 100 × Net income attributable to Medtronic ÷ Shareholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income attributable to Medtronic ÷ Shareholders’ equity
= 100 × ÷ =


Net Income Analysis
The reported net income attributable to Medtronic exhibited fluctuations over the observed periods. From April 2020 to April 2021, there was a notable decline from 4,789 million to 3,606 million US dollars. This was followed by an increase in April 2022 to 5,039 million, before declining again in the subsequent two years to 3,676 million in April 2024. The latest data point in April 2025 indicates a recovery, with reported net income rising to 4,662 million US dollars.
The adjusted net income followed a somewhat similar pattern but with less pronounced amplitude. It started at 4,834 million in April 2020, decreased to 3,698 million in April 2021, and then showed a more moderate variation in the following years, ending at 4,811 million in April 2025. The adjusted figures suggest a smoothing of volatile elements seen in the reported net income.
Return on Equity (ROE) Analysis
Reported ROE demonstrated variability aligning with the trends in reported net income. It decreased from 9.44% in April 2020 to a low of 7.01% in April 2021, then rose to 9.59% in April 2022 before dipping again to around 7.3% in the next two years. The ROE improved to 9.71% in April 2025, indicative of improved profitability relative to shareholders' equity.
Adjusted ROE tracked a similar trajectory but generally maintained a slightly higher level compared to reported ROE in the later periods. Starting at 9.53% in April 2020, it dropped to 7.19% in April 2021, then fluctuated with a modest recovery to 10.02% by April 2025. The adjusted ROE suggests that, when adjusting for certain factors, the company’s return to equity improved more consistently in the latest period.
Overall Trends and Insights
The data reveal a cyclical pattern in earnings and profitability, with significant drops observed in the periods ending April 2021 and April 2024, and recovery phases thereafter. The adjusted figures provide a more stable view, reducing the impact of exceptional or non-recurring items. The improvement in adjusted ROE in the latest period signals enhanced efficiency in generating shareholder returns when accounting for adjustments. The median decline and subsequent recovery in both reported and adjusted metrics may reflect external market conditions or internal company dynamics affecting performance.
In summary, the financial performance shows resilience with periods of volatility, but a positive trend emerges towards the most recent fiscal year, highlighting potential strengthening of profitability and shareholder value generation.

Adjusted Return on Assets (ROA)

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic
Total assets
Profitability Ratio
ROA1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Medtronic
Total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

2025 Calculations

1 ROA = 100 × Net income attributable to Medtronic ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income attributable to Medtronic ÷ Total assets
= 100 × ÷ =


The financial data presents a mixture of reported and adjusted metrics related to net income and return on assets (ROA) over a six-year period.

Net Income Trends
The reported net income attributable shows significant fluctuations throughout the period. It initially declines from 4,789 million US dollars in 2020 to 3,606 million in 2021, followed by a recovery to 5,039 million in 2022. Subsequently, it decreases again over the next two years to reach 3,676 million in 2024, before rising to 4,662 million in 2025.
The adjusted net income also follows a somewhat cyclical pattern but with less volatility. Starting at 4,834 million in 2020, it dips to 3,698 million in 2021, then decreases again to 4,738 million in 2022, and experiences a drop to 3,709 million in 2023. After this, it shows a gradual increase to 4,811 million by 2025. The adjusted figures tend to smooth out some of the sharp variations seen in the reported numbers, indicating certain adjustments impacting reported net income figures.
Return on Assets (ROA) Patterns
The reported ROA fluctuates in a pattern similar to net income. It decreases from 5.28% in 2020 to 3.87% in 2021, recovers to 5.54% in 2022, then falls again to approximately 4.09% in 2024 before rising to 5.09% in 2025. This indicates varying efficiency in asset utilization relative to net income performance.
The adjusted ROA shows slightly more stability compared to reported ROA, with values starting at 5.33% in 2020, dipping to 3.97% in 2021, then moderating around 5.21% in 2022 and maintaining levels close to 4.14% in 2024. It ultimately improves to 5.25% in 2025. The adjusted ROA maintains a tight range near the reported figures but reflects the impact of adjustments in profitability measurements relative to asset base.
Overall Observations
Both net income and ROA reveal a pattern of volatility with a general decline in 2021 followed by partial recovery, subsequent dips, and improvement towards 2025. The adjusted figures provide a smoother trajectory, indicating that certain extraordinary items or non-recurring events might have contributed to the fluctuations in reported data.
The recovery trend observed in 2025 for both net income and ROA, on both reported and adjusted bases, points to an improving profitability and asset utilization environment.